A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
Recruiting
99 years and younger
All
Phase
2
4 participants needed
1 Location
Brief description of study
Evaluate the safety, tolerability, and immunogenicity of 3 dose levels of PR006A administered via sub-occipital injection into the cisterna magna and Quantify PGRN levels in blood and CSF. Please refer to section 2 of the attached protocol. Please refer to section 2 of the attached protocol.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
09 Feb 2022.
Study ID: 844811
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
